NCT05155332 2026-04-14
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Recruiting
Boehringer Ingelheim
Ann & Robert H Lurie Children's Hospital of Chicago
University of Wisconsin, Madison
University of Pittsburgh
University Health Network, Toronto
Guangzhou FineImmune Biotechnology Co., LTD.
Chinese PLA General Hospital